HCi Viocare Commences Trading on Berlin Stock Exchange

GLASGOW, SCOTLAND--(Marketwired - Apr 27, 2016) - HCi Viocare (OTCQB: VICA), a Nevada corporation (the "Company"), today announced it has been approved for a joint listing on the Berlin Stock Exchange (the "BSE"). The Company is currently trading on the OTC Markets Group, Inc. QB Tier (OTCQB) in the United States and has decided, in the best interests of its shareholders, to list on a European platform to better accommodate its European shareholders and investors. The Company has received the trading symbol "HCF" on the BSE, Security WKN # A2AG73 and ISIN # US40416H2058.

The Berlin Stock Exchange or Börse Berlin AG is one of the oldest stock exchanges in Germany. The BSE has pursued a successful niche strategy since the mid-nineties, with a particular focus on trading the widest possible range of foreign stocks.

Sotiris Leontaritis, HCi Viocare's CEO, comments: "This dual listing improves liquidity and opens up a much broader range of funders, investors, and potential shareholders to the Company. It will allow HCi Viocare to better serve its current and future European investors."

The Company believes a dual listing on the Berlin Stock Exchange will:

• Improve the Company's image, reputation and prestige as a global participant;
• Greatly expand the ability of the Company to raise equity or debt financing in the future;
• Increase the Company's trading volume and liquidity;
• Improve the Company's shareholder relations; and
• Vastly enhance the visibility of the Company among overseas investors and consumers.

About HCi Viocare

HCi Viocare has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a wide portfolio of proprietary hardware solutions with first in line the Flexisense™ sensor system, aiming to empower the user by providing on demand information in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports and Wellbeing, and licensing to established industry participants. HCi Viocare is listed on the OTC Markets in the USA, has its executive office in Athens, Greece and R&D center in Glasgow, UK.

Company website: www.hciviocare.com
Glasgow clinic website: www.hci-viocare.co.uk
FlexisenseTM: http://flexisense.hciviocare.com/
Twitter: @HCiViocare

UK-Glasgow location:
HCi Viocare, Kintyre House, 209 Govan Road, Glasgow G51 1HJ

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects': "intends", "estimates': "projects", "anticipates': "believes': "could': and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC'). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company has only recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a its force sensing technology with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.